Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human use

Biomedicine and Pharmacotherapy

Volumn 54, Issue 1, 2000, Pages 41-44

  Le Buanec, H ^a   Bizzini, B ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

HIV 1; Tat; Toxoid; Vaccination

Indexed keywords

INTERLEUKIN 4; TOXOID; TUBERCULIN; VIRUS PROTEIN;

AFFINITY CHROMATOGRAPHY; AMIDATION; ARTICLE; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; PRIORITY JOURNAL; TRANSACTIVATION; VACCINATION; VIRUS ISOLATION;

EID: 0034143245     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88639-4     Document Type: Article

References (10)

1. Zagury D. A naturally unbalanced combat. Nature Med 1997 ; 3 : 156-7.
2. Ramon G. Sur le pouvoir floculant et les propriétés immunisantes d'une toxine diphtérique rendue anatoxique (anatoxine) CR Hebd Séances Acad Sci 1923 ; 177 : 1338-40.
3. Rappaport J, Lee SJ, Khalili K, Wong-Staal F. The acidic amino-terminal region of HIV-1 Tat protein constitutes an essential activating domain. New Biol 1989 ; 1 : 101-10.
4. Frankel AD, Pabo CO. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988 ; 55 : 1189-93.
5. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Moll Cell Biol 1982 ; 2 : 1044-51.
6. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998 ; 95 : 3851-6.
7. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Virol 1981 ; 37 : 755-8.
8. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncellis, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999 ; 5 : 643-50.
9. Gringeri A, Santagostino E, Muça-Perja M, Le Buanec H, Bizzini B, Lachgar A, et al. Tat-Toxoid, a safe and immunogenic component for a preventive vaccine in seronegative subjects. JAIDS 1999 ; 20 : 371-5.
10. Gringeri A, Santagostino E, Muça-Perja M, Manucci PM, Zagury JF, Bizzini B, et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1 infected patients. J Hum Virol 1998 ; 1 : 293-8.